1. Press Release
VOLUNTIS AND ASTRAZENECA TO TEST COMPANION MOBILE
APP IN OVARIAN CANCER STUDIES WITH THE US NATIONAL
CANCER INSTITUTE
7 December 2015
Voluntis and AstraZeneca today announced plans to test a digital support service for women
undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical
trials of cediranib plus olaparib. Voluntis developed the service in close clinical collaboration
with AstraZeneca and the US National Cancer Institute (NCI). It is delivered through a
smartphone app paired with a web portal to help clinicians and patients manage side effects of
hypertension and diarrhoea sometimes associated with combination therapy with cediranib
and olaparib. Such side effects are traditionally described to care teams through manual, time-
consuming and non-digitised channels.
The app will be tested as a companion device in three separate clinical trials sponsored by the
NCI beginning in the first quarter of 2016, under a Cooperative Research and Development
Agreement between the NCI and AstraZeneca. This approach illustrates a clear focus on
understanding the patient journey when developing therapeutic solutions. The service will also
serve as a pilot within AstraZeneca’s broader strategy of using digital technology to
complement treatment and to improve patient outcomes.
Antoine Yver, Head of Oncology, Global Medicines Development at AstraZeneca, said:
“Empowering patients with this smartphone-based app gives them greater control of their
treatment and management of their response. The support it provides can further reduce
medication dose modification and discontinuation rates and help maintain patients on therapy
to improve their treatment outcome.”
Pierre Leurent, Chief Executive Officer of Voluntis, said: “We are delighted to be partnering
with AstraZeneca for this project. AstraZeneca has a strong focus on the use of companion
devices in drug development. Their approach, combined with our technological, medical and
regulatory expertise provides the perfect synergy to create a personalised therapeutic solution
that goes beyond the pill to best serve the needs of patients and their health care providers.”
– ENDS –
NOTES TO EDITORS
About cediranib
Cediranib is a highly potent, selective, orally-administered inhibitor of VEGF-1, -2 and -3
receptors. It has been shown to inhibit angiogenesis and lymphangiogenesis in the
vascularization of platinum sensitive tumor types. In July 2015, cediranib filing was accepted
by the European Medicines agency and awarded Orphan Drug status for the treatment of
platinum sensitive relapse ovarian cancer. Cediranib also in development, in combination with
Lynparza (olaparib), for platinum sensitive relapse ovarian cancer and platinum resistant
relapse ovarian cancer.
About olaparib

2. Press Release
2
Olaparib is an innovative, first-in-class oral poly ADP-ribose polymerase (PARP) inhibitor that
exploits tumour DNA repair pathway deficiencies to preferentially kill cancer cells. This mode
of action gives olaparib the potential for activity in a range of tumour types with DNA repair
deficiencies. Olaparib is the first PARP inhibitor to be approved for patients with germline
BRCA-mutated advanced ovarian cancer, and has been launched in the U.S. and Europe,
with ongoing regulatory submissions across multiple markets. In addition to ovarian cancer,
AstraZeneca is investigating the full potential of olaparib in multiple tumour types, with Phase
III studies in second line gastric cancer, BRCA-mutated pancreatic cancer and adjuvant and
metastatic BRCA-mutated breast cancers underway.
About Voluntis
Pioneering therapeutic companion software, Voluntis innovates healthcare by embedding
connectivity in therapeutics and medical intelligence in software. Dedicated to managing
chronic conditions, Voluntis’ companion software aim to enable treatment personalisation, to
support team-care coordination and to improve real-world outcomes. Harnessing its
proprietary technology, Voluntis has developed digital solution for diabetes, respiratory
diseases, cancer, anticoagulation treatments and haemophilia. Voluntis is headquartered in
Paris, France, and has offices in Boston, USA. For more information, visit www.voluntis.com.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the
discovery, development and commercialisation of prescription medicines, primarily for the
treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology,
infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide. For more information please
visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Amélie Janson amelie.janson@voluntis.com +33 1 80 03 19 52
+33 6 03 29 06 45